Vaxcyte, Inc. (PCVX)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow PCVX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on PCVX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
PCVX at a glance
Key statistics
$10.42B
Market capitalization
- Previous close
- $66.23
- Open
- $66.25
- Day range
- $63.12 – $67.43
- Volume
- 1.92M
- Average volume (30 sessions)
- 2.99M
- Shares outstanding
- 148.81M
- Earnings per share
- $(6.76)
- Price / book
- 3.8
- Beta (1 year, vs SPY)
- 1.10
Where the price sits in its year
52-week range
47% of the range
- Below the 52-week high
- -29.4%
- Above the 52-week low
- +60.6%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $63.08+5.0%
- 50-day average
- $61.35+8.0%
- 200-day average
- $56.42+17.4%
Between the conventional 30 and 70 bands.
-0.9%
1 week
+12.4%
1 month
+18.3%
3 months
+43.5%
Year to date
+56.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with PCVX
PCVX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on PCVX.
See the plans →
Every planScreen names like PCVX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on PCVX
Put PCVX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on PCVX
See whether there is an open premium alert on PCVX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
PCVX headlines
- Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
GlobeNewswire Inc. · Oct 6, 2026
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
GlobeNewswire Inc. · Mar 18, 2026
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Benzinga · Feb 2, 2026
- Vaxcyte Announces Pricing of $550 Million Public Offering
GlobeNewswire Inc. · Jan 29, 2026
- Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
GlobeNewswire Inc. · Jan 22, 2026
- Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Benzinga · Mar 31, 2025
- Vaxcyte Announces Pricing of $1.3 Billion Public Offering
GlobeNewswire Inc. · Sep 4, 2024
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc. · Sep 3, 2024
SEC Form 4, most recent first
Insider filings
Wassil Jim
−18.0K
EVP, Chief Scientific Ofc, COO · Open-market sale
$1.56M · Oct 5, 2026
Wassil Jim
+18.0K
EVP, Chief Scientific Ofc, COO · Option exercise
$96.30K · Oct 5, 2026
Wassil Jim
−18.0K
EVP, Chief Scientific Ofc, COO · Option exercise
· Oct 5, 2026
Cowan Elvia
−19.0K
SVP, Finance & CAO · Open-market sale
$1.65M · Oct 5, 2026
Cowan Elvia
−19.0K
SVP, Finance & CAO · Option exercise
· Oct 5, 2026
Cowan Elvia
+19.0K
SVP, Finance & CAO · Option exercise
$492.48K · Oct 5, 2026
Wassil Jim
−2.3K
EVP, Chief Scientific Ofc, COO · Option exercise
· Oct 1, 2026
Wassil Jim
+2.3K
EVP, Chief Scientific Ofc, COO · Option exercise
$12.04K · Oct 1, 2026
About Vaxcyte, Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- San Carlos, CA
- Employees
- 507
- Listed since
- Jun 12, 2020
- Website
- vaxcyte.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.